Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date	Title and Summary	View
Jul 29, 2021	PTC Therapeutics Provides a Corporate Update and Reports Second Quarter 2021 Financial Results - Total quarterly net revenue of $117 million; 55% increase over second quarter 2020 - - Raises 2021 DMD franchise revenue guidance to $370-$390M from $355-$375M - - Progress across robust clinical pipeline with 3 ongoing registration-directed trials - SOUTH PLAINFIELD, N.J.	Additional Formats
Jul 28, 2021	Significant Improvements in Survival and Developmental Milestones Demonstrated in Type 1 SMA Patients Treated with Evrysdi™ - Results from Part 2 of FIREFISH pivotal study published in the New England Journal of Medicine - SOUTH PLAINFIELD, N.J. , July 28, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that results from Part 2 of the FIREFISH pivotal study were published in the New England	Additional Formats
Jul 15, 2021	PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2021 Financial Results SOUTH PLAINFIELD, N.J. , July 15, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its second quarter 2021 financial results and provide an update on the company's business and outlook on Thursday, July 29,	Additional Formats
Jun 24, 2021	Results Add to Body of Evidence Confirming EMFLAZA®'s Benefit Over Prednisone - Data presented at the 2021 Parent Project Muscular Dystrophy Annual Conference - SOUTH PLAINFIELD, N.J. , June 24, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today presented pooled placebo data from multiple studies in which the results confirmed the clinical benefit of EMFLAZA ®	Additional Formats
Jun 23, 2021	Evrysdi™ Approved in Japan for the Treatment of Spinal Muscular Atrophy - 48th country that approved Evrysdi - - First commercial sale in Japan will trigger $10M milestone payment from Roche - SOUTH PLAINFIELD, N.J. , June 23, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Evrysdi™ (risdiplam) was approved in Japan by the Japanese	Additional Formats
Jun 15, 2021	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SOUTH PLAINFIELD, N.J. , June 15, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on June 11, 2021 it approved non-statutory stock options to purchase an aggregate of 118,350 shares of its common stock and 30,835 restricted stock units ("RSUs"), each representing the	Additional Formats
Jun 11, 2021	Pre-symptomatic Infants with Spinal Muscular Atrophy Achieved Same Motor Milestones as Healthy Children After Treatment with Evrysdi™ in RAINBOWFISH - JEWELFISH results demonstrated stabilization in motor function in broad SMA population - - Evrysdi has proven efficacy in adults, children and babies two months and older - - Results presented at CureSMA Conference - SOUTH PLAINFIELD, N.J. , June 11, 2021 /PRNewswire/ -- PTC Therapeutics, Inc.	Additional Formats
Jun 09, 2021	Health and Human Services Expert Mary L. Smith Joins PTC Therapeutics' Board of Directors SOUTH PLAINFIELD, N.J. , June 9, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the election of Mary L. Smith to the Company's Board of Directors. Ms. Smith has previously served as the Principal Deputy Director and CEO equivalent at the Indian Health Service , a $6	Additional Formats
May 26, 2021	PTC Therapeutics Announces Orphan Drug Designations of PTC923 for the Treatment of Hyperphenylalaninemia SOUTH PLAINFIELD, N.J. , May 26, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that both the United States Food and Drug Administration (FDA) and European Commission (EC) have granted Orphan Drug Designation (ODD) for PTC923 for the treatment of patients with	Additional Formats
May 19, 2021	PTC Therapeutics to Participate at Upcoming Virtual Investor Conference SOUTH PLAINFIELD, N.J. , May 19, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the following conference: William Blair 41 st Annual Growth Stock Conference Wednesday, June 2 nd at 3:40 p.m.	Additional Formats